National Institute for Health and Care Excellence

March 29, 2019

UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients

News

After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell ... Read more

February 8, 2019

U.K. Institute Recommends Kymriah for Adults with Aggressive DLBCL

News

The U.K.’s National Institute for Health and Care Excellence (NICE) has recommended that Kymriah (tisagenlecleucel) be offered to patients with difficult-to-treat diffuse large B-cell lymphoma (DLBCL) through the Cancer Drugs Fund. Specifically, this Novartis-developed therapy ... Read more

January 10, 2019

Adcetris Not Cost-effective as Second-line Therapy for Some CTCL, U.K. Board Rules

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) concluded that Adcetris (brentuximab vedotin) is not a cost-effective option when given as a second-line therapy to people with ... Read more

February 15, 2016

Last Week’s Hot Topic on Lymphoma

Last week’s hot topic on Lymphoma was about the NICE Updating Non-Hodgkin’s Lymphoma Guideline to Reflect New Treatment Options written by Carolina Henriques. The article is centered around the NICE updating its position on the ... Read more